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Serum Albumin Is Inversely Associated 
With Portal Vein Thrombosis in Cirrhosis
Stefania Basili,1* Roberto Carnevale,2* Cristina Nocella,3 Simona Bartimoccia,1 Valeria Raparelli,4,5 Giovanni Talerico,1  
Lucia Stefanini,1 Giulio F. Romiti,1 Francesco Perticone,6 Gino R. Corazza,7 Fabio Piscaglia,8 Antonello Pietrangelo,9  
Francesco Violi,1 and PRO-LIVER Collaborators
We analyzed whether serum albumin is independently associated with portal vein thrombosis (PVT) in liver cir-
rhosis (LC) and if a biologic plausibility exists. This study was divided into three parts. In part 1 (retrospective 
analysis), 753 consecutive patients with LC with ultrasound-detected PVT were retrospectively analyzed. In part 2, 
112 patients with LC and 56 matched controls were entered in the cross-sectional study. In part 3, 5 patients with 
cirrhosis were entered in the in vivo study and 4 healthy subjects (HSs) were entered in the in vitro study to explore 
if albumin may affect platelet activation by modulating oxidative stress. In the 753 patients with LC, the prevalence 
of PVT was 16.7%; logistic analysis showed that only age (odds ratio [OR], 1.024; P = 0.012) and serum albumin 
(OR, −0.422; P = 0.0001) significantly predicted patients with PVT. Analyzing the 112 patients with LC and con-
trols, soluble clusters of differentiation (CD)40-ligand (P = 0.0238), soluble Nox2-derived peptide (sNox2-dp; 
P < 0.0001), and urinary excretion of isoprostanes (P = 0.0078) were higher in patients with LC. In LC, albumin 
was correlated with sCD40L (Spearman’s rank correlation coefficient [rs], −0.33; P < 0.001), sNox2-dp (rs, −0.57; 
P < 0.0001), and urinary excretion of isoprostanes (rs, −0.48; P < 0.0001) levels. The in vivo study showed a pro-
gressive decrease in platelet aggregation, sNox2-dp, and urinary 8-iso prostaglandin F2α-III formation 2 hours and 
3 days after albumin infusion. Finally, platelet aggregation, sNox2-dp, and isoprostane formation significantly 
decreased in platelets from HSs incubated with scalar concentrations of albumin. Conclusion: Low serum albumin in 
LC is associated with PVT, suggesting that albumin could be a modulator of the hemostatic system through inter-
ference with mechanisms regulating platelet activation. (Hepatology Communications 2019;3:504-512).
There is overwhelming evidence that cirrho-sis may be complicated not only by bleed-ing episodes but also by venous thrombosis, 
which occurs mainly in the portal vein but may also 
be detected in the systemic circulation.(1) The prev-
alence of portal vein thrombosis (PVT) is approxi-
mately 15% in cirrhosis, whereas its incidence is 
roughly 2% per year in patients without a history of 
venous thrombosis.(2-6) PVT occurs more frequently 
in patients with cirrhosis who are 67 years of age in 
average or in those with a history of venous throm-
bosis or hepatocellular carcinoma (HCC).(5) Liver 
decompensation is another important factor associ-
ated with PVT, as demonstrated by a more frequent 
association between PVT and Child-Pugh classes B 
and C; however, the underlying mechanism is still 
undefined.(5-7) Venous stasis, which is a key com-
ponent of the Virchow triad, likely plays a role in 
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patients with advanced disease, but the contribution 
of other mechanisms implicated, for instance, in clot-
ting or platelet activation, is poorly understood. We 
have previously shown that serum albumin, which 
is a component of the Child-Pugh score, is lower in 
patients with cirrhosis with PVT compared to those 
without, but it is still unclear whether this finding is a 
mere epiphenomenon of the underlying liver disease, 
thereby unrelated to PVT development, or conversely 
has a pathophysiologic value in the context of clot-
ting/platelet activation and eventually thrombosis.(5) 
Because previous studies demonstrated an associa-
tion between serum albumin and thrombosis in the 
setting of cardiovascular disease,(8,9) the aim of the 
present study was to investigate if serum albumin was 
associated with PVT independently from Child-Pugh 
score and if a biologic plausibility between serum 
albumin and thrombosis exists. As to the latter, we 
performed in vivo and in vitro studies to explore if 
albumin affects platelet activation and if so, what the 
underlying mechanism is, focusing in particular on its 
potential capability of modulating intracellular oxida-
tive stress.
Patients and Methods
We divided this study into three parts. Part 1 was a 
retrospective analysis of the association between PVT 
and Child-Pugh score components (ascites, enceph-
alopathy, bilirubin, prothrombin time–international 
normalized ratio [PT-INR], albumin), age, and sex. 
Part 2 was a cross-sectional study to analyze the cor-
relation between serum albumin, one of the laboratory 
variables included in the Child-Pugh score, and plate-
let activation and oxidative stress indexes. Part 3 was 
an in vivo and in vitro investigation studying the pos-
sible influence of albumin on platelet activation by 
modulation of oxidative stress.
patients
In part 1, 753 (68% men; 64 ± 12 years) patients 
were enrolled in the Portal Vein Thrombosis Relevance 
on Liver Cirrhosis: Italian Venous Thrombotic Events 
Registry (PRO-LIVER; ClinicalTrials.gov identifier, 
NCT01470547).(5) The study was an Italian multi-
center study with the primary aim of estimating the 
prevalence of PVT in a cohort of patients with liver 
cirrhosis (LC). Patients with LC of any etiology and 
grade who were referred to any of the 43 participat-
ing centers were consecutively enrolled in the study. 
At baseline, each patient underwent a Doppler ultra-
sound examination of the portal vein and its branches 
to assess the presence of PVT. At enrollment, data 
on medical history, comorbidities, and severity of cir-
rhosis were registered (measured by Child-Pugh and 
Model for End-Stage Liver Disease scores) as well as 
several laboratory data (including serum creatinine, 
serum albumin, total bilirubin, and PT). PVT was 
first suspected when solid endoluminal material was 
detected in the main trunk of the portal vein and/or 
its branches, and it was then confirmed by demon-
strating a filling defect on Doppler examination. 
PVT was classified as complete/incomplete according 
to the absence/presence of any residual blood flow. 
According to these criteria, PVT was detected in 17% 
(n = 126) of patients.
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Clinical and laboratory characteristics of patients 
according to the presence or absence of PVT have 
been depicted.(5) Briefly, patients with LC with PVT 
were older and showed a more advanced and decom-
pensated disease with higher prevalence of Child-
Pugh B and C classes (63% versus 44%) than patients 
without PVT. Patients with PVT more often had a 
history of previous recanalized PVT (20% versus 4%) 
and higher HCC prevalence (35% versus 17%).
In part 2, a second cohort of patients with LC was 
enrolled to analyze the interplay between serum albu-
min levels and markers of platelet activation/oxidative 
stress. For this purpose, 112 patients (65 of A, 31 of 
B, and 16 of C Child-Pugh classes) without history 
of previous PVT, concomitant HCC, and free from 
PVT at enrollment were included in the study. As a 
control group, 56 patients without LC, matched for 
the presence of concomitant atherosclerotic risks and 
not taking any drug interfering with the clotting sys-
tem, were selected (Table 1). Blood and urine sam-
ples of every study subject were stored at −80°C until 
use. The study was conducted in accordance with the 
European Union Note for Guidance of Good Clinical 
Practice and the Declaration of Helsinki. Informed 
consent was obtained for each participant prior to 
inclusion in the study.
In part 3, we enrolled 5 patients with cirrhosis 
(4 male patients and 1 female patient; aged 54-78 
years). During hospitalization, they received infusion 
of human albumin (40 g/day) for 3 days; thereaf-
ter, blood samples were taken 4 days after albumin 
discontinuation.
Blood was collected in vacutainer tubes with and 
without anticoagulant between 8:00 and 9:00 AM at 
four time points: baseline, 2 hours later, at 3 days, and 
at 7 days. Samples were centrifuged for 15 minutes at 
180g for analysis of platelet aggregation or 10 minutes 
at 300g for analysis of soluble Nox2-derived peptide 
(sNox2-dp), as reported below. Urinary samples were 
taken at the same time for the analysis of 8-iso pros-
taglandin F2α-III (8-iso-PGF2α-III).
IN VITRO stuDy
platelet preparation and aggregation
To obtain platelet-rich plasma (PRP), citrated 
blood samples taken from healthy subjects (HSs) 
(n = 4; male patients 2, female patients 2; aged 39.7 ± 
7.6 years) were centrifuged for 15 minutes at 180g. To 
avoid leukocyte contamination, only the top 75% of 
the PRP was collected according to Pignatelli et al.(10) 
Platelet-poor plasma was prepared by centrifug-
ing the remaining sample at 300g for 10 minutes at 
room temperature. PRP was stimulated with collagen 
(2 µg/mL), and light transmission was recorded over 
10 minutes in a two dual-channel module ChronoLog 
Model 700 light transmission aggregometer.
To obtain washed platelets for in vitro study, PRP 
was treated with acid citrate dextrose (10/1 volume 
[vol]/vol), centrifuged at 300g for 10 minutes (twice) 
in the presence of prostaglandin E1 (1 µM), and 
finally suspended (2 × 108 platelets/mL) in albu-
min-free Tyrode’s buffer containing 137 mmol/L 
NaCl, 0.3 mmol/L Na2HPO4, 2 mmol/L KCl, 12 
NaHCO3, 5 mmol/L N-2-hydroxyethylpiperazine-
N′-2-ethanesulfonic acid, 5 mmol/L glucose pH 7.3, 
and 1 mM CaCl2.
Washed platelets were pre-incubated (15 minutes 
at 37°C) with albumin at 2, 2.5, 3, 3.5, and 4 g/dL, 
activated with collagen (2 µg/mL), and light transmis-
sion recorded. Experiments were performed at 37°C 
in the presence of 50 μg/mL fibrinogen and under 
stirring conditions.
After stimulation with agonist, samples were cen-
trifuged for 3 minutes at 3,000g. Supernatants were 
taBle 1. CliniCal anD laBoRatoRy 
CHaRaCteRistiCs oF patients  
WitH CiRRHosis WitHout poRtal  
Vein tHRomBosis anD matCHeD  
ContRols (paRt 2)
Controls Cirrhosis
P(n = 56) (n = 112)
Age, years 64 ± 13 66 ± 8 0.3559*
Sex male, n (%) 33 (59) 67 (60) 0.9115#
Comorbidities:
CVD, n (%) 17 (30) 27 (24) 0.3850#
Diabetes, n (%) 22 (39) 39 (35) 0.3217#
Serum albumin (g/dL) 3.74 ± 0.42 3.40 ± 0.58 0.0002*
sCD40L (ng/mL) 8.0 9.5 0.0238†
[5.0-10.0] [5.0-16]
sNox2-dp (pg/mL) 11.9 24.0 <0.0001†
[9.0-13.6] [15.0-36.5]
Urinary 8-iso-PGF2α-III 
(pg/mg creatinine)
145.0 260.0 <0.001†
[125.0-155.5] [122.5-438.0]
Data are expressed as median [IQR] or mean ± SD.
*t test; †Mann-Whitney U Test; #chi-square test.
Abbreviation: CVD, cardiovascular disease.
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stored at −80°C for analysis of sNox2-dp levels and 
8-Iso-PGF2α–III formation. The intra-assay and 
interassay coefficients of variation for aggregation test 
were 5.7% and 6.8%, respectively.
integrin αiibβ3 activation
Platelets washed in albumin-free Tyrode’s buf-
fer were diluted to a concentration of 3 × 107 plate-
lets/mL in Tyrode’s buffer containing 0, 2.5, 3, 3.5, 
and 4 mg/dL of bovine serum albumin (fraction V; 
Sigma-Aldrich). After 15 minutes of rest, platelets 
were activated with 10 ng/mL convulxin (Kenneth 
Clemetson, Theodor Kocher Institute, University of 
Berne, Switzerland) in the presence of 1 mM CaCl2 
and 5 μg/mL pituitary adenylate cyclase-activating 
polypeptide type I receptor-fluorescein isothiocyanate 
(BD Biosciences), an antibody directed toward the 
activated form of human αIIbβ3. Following 10 min-
utes of incubation, samples were diluted with 1 mL 
of phosphate-buffered saline and analyzed immedi-
ately with a BD Accuri C6 Plus flow cytometer (BD 
Biosciences). Data are shown as the percentage of 
maximal activation (mean ± SD).
serum and platelet snox2-dp
Serum and platelet Nox2 activity were measured 
as sNox2-dp with an enzyme-linked immunosor-
bent assay (ELISA) method as reported.(11) Briefly, 
reference standards of known concentrations of 
sNox2-dp and samples (1 mg of protein) were coated 
into ELISA 96-well plates overnight at 4°C. Anti-
sNox2-dp–horseradish peroxidase (HRP) monoclonal 
antibody was added to each well, and immobilized 
antibody enzyme conjugates were quantified by mon-
itoring HRP activities in the presence of the substrate 
3,3′,5,5′-tetramethylbenzidine. Enzyme activity was 
measured spectrophotometrically by the increased 
absorbency at 450 nm after acidification of formed 
products (2 M sulphuric acid). Values were expressed 
as pg/mL; intra-assay and interassay coefficients of 
variation were <10%.
urinary and platelet 8-iso-pgF2α 
assays
Urinary and platelet isoprostane (8-iso-PGF2α-III) 
were measured by the enzyme immunoassay method 
(DRG International, Springfield Township, NJ) and 
expressed as pg/mg creatinine or pmol/L. Intra-assay 
and interassay coefficients of variation were 5.8% and 
5.0%, respectively.
plasma sCD40l
Soluble clusters of differentiation (sCD)40L was 
measured in citrated blood samples centrifuged 10 
minutes at 300g. sCD40L levels were evaluated by a 
commercial immunoassay (DRG International), and 
values were expressed as ng/mL; intra-assay and inter-
assay coefficients of variation were <10%.
statistiCal analysis
All continuous variables were tested for normality 
with the Shapiro-Wilk test. Variables with normal 
distribution were expressed as mean ± SD and tested 
for differences with the Student t test with, if nec-
essary, Bonferroni’s correction. Non-normal variables 
were expressed as median and interquartile range, and 
differences were tested with the Mann-Whitney U 
test. Multiple linear regression and logistic regression 
analyses were also performed. Stochastic level of entry 
into the model was set at P = 0.10, and interaction 
terms were explored for all the variables in the final 
model. Only P < 0.05 was regarded as statistically sig-
nificant. All tests were two tailed, and analyses were 
performed using computer software packages (SPSS, 
version 22.0; IBM, Armonk, NY).
Results
paRt 1
In accordance with our previous report, 126 patients 
with PVT at baseline had lower albumin serum levels 
(3.1 ± 0.6 versus 3.4 ± 0.6 g/dL; P < 0.0001) than 
627 patients without PVT.(5) Comparing patients 
with PVT with Child-Pugh A (n = 45 out of 397; 
11%) versus those in classes B and C (n = 81 out 
of 356; 23%), PVT was consistently associated with 
lower levels of serum albumin (Fig. 1A,B). We used 
multiple regression to analyze the association between 
Child-Pugh score components (ascites, encephalopa-
thy, bilirubin, PT-INR, albumin), age, sex, and PVT. 
The final model (F [regression mean square] = 4.5; 
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P < 0.0006) showed that only age (beta coefficient, 
0.10; SEM, 0.04; P = 0.014) and serum albumin (beta 
coefficient, −0.14; SEM, 0.05; P = 0.0051) were inde-
pendently associated with PVT. By excluding the 152 
patients with HCC at baseline, the multivariate anal-
ysis confirmed that only serum albumin was signifi-
cantly inversely correlated with PVT (beta coefficient, 
−0.16; SEM, 0.06; P = 0.0042).
To corroborate the data regarding the relation 
between PVT at entry and Child-Pugh score com-
ponents, a logistic regression analysis was also per-
formed; the final model (stepwise forward method) 
confirmed that only age (odds ratio [OR], 1.024; 95% 
confidence interval [CI], 1.005-1.043; P = 0.012) and 
serum albumin (OR, 0.422; 95% CI, 0.293-0.608; 
P = 0.0001) significantly predicted patients with PVT.
paRt 2
Analyzing the 112 patients with LC and matched 
control subjects, sCD40L plasma levels (P = 0.0238), 
sNox2-dp serum levels (P < 0.0001), as well as urinary 
excretion of isoprostanes (P = 0.0078) were significantly 
higher in LC than in control (Table 1). In patients with 
LC, serum albumin levels were significantly correlated 
with sCD40L ([rs] = −0.33; P < 0.001), sNox2-dp 
serum levels (rs = −0.57; P < 0.0001), and urinary 
excretion of isoprostanes (rs = −0.48; P < 0.0001) 
(Fig. 2A-C).
paRt 3: IN VIVO stuDy
Serum albumin levels were 1.57 ± 0.51 g/dL at 
baseline (Fig. 3A) and progressively increased after 2 
hours and 3 days (Fig. 3A); 4 days after albumin dis-
continuation, serum albumin tended to return to base-
line values (Fig. 3A). Compared to baseline, platelet 
aggregation, serum levels of sNox2-dp, and urinary 
8-iso-PGF2α-III formation were significantly low-
ered (Fig. 3B-D); conversely, 4 days after albumin dis-
continuation, they all increased (Fig. 3B-D).
paRt 3: IN VITRO stuDy
Platelets from healthy volunteers were incubated 
with scalar concentrations of albumin (2.5, 3, 3.5, and 
4 g/dL). After stimulation, albumin-treated platelets 
showed a significant decrease of platelet aggregation 
(Fig. 4A) and αIIbβ3 activation (Fig. 4B) compared 
to controls; this effect was already evident at con-
centrations of 2.5 g/dL. Coincidentally, we found a 
significant reduction of platelet sNox2-dp levels and 
isoprostane formation (Fig. 4C,D).
Fig. 1. Albumin serum levels according to presence of venous portal thrombosis in patients with liver cirrhosis (n = 753). (A) Patients 
with liver cirrhosis in Child-Pugh A. (B) Patients with liver cirrhosis in Child-Pugh B and C classes. Abbreviation: US, ultrasound.
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Discussion
This study provides evidence that serum albumin is 
inversely associated with PVT in patients with cirrho-
sis and suggests albumin as a modulator of the hemo-
static system through interference with mechanisms 
regulating platelet activation. In particular, we demon-
strate that albumin interferes with platelet activation 
by inhibiting Nox2-mediated oxidative stress.
Previous studies consistently showed that PVT is 
more often associated with advanced liver disease, but 
the underlying mechanism was unclear. In the present 
analysis of the PRO-LIVER study population, which 
investigated the predictors of PVT in patients with 
cirrhosis, we found that serum albumin was lower 
in patients presenting with PVT compared to those 
without PVT and was independently associated with 
PVT after adjustment for several factors, including 
degree of liver failure as assessed by Child-Pugh 
score. In accordance with this, serum albumin was 
associated with PVT not only in patients of Child-
Pugh classes B and C but also in those of class A, 
reinforcing the hypothesis that albumin per se may be 
a major determinant of PVT occurrence. Our data are 
consistent with previous reports showing an inverse 
relationship between serum albumin and arterial and 
venous thrombotic events.(8,12)
To explore the biological plausibility of this find-
ing, we performed in vivo and in vitro experiments 
to test the hypothesis that albumin interferes with 
mechanisms favoring the thrombotic process. In a first 
set of experiments, we investigated whether serum 
albumin is associated with markers of in vivo platelet 
activation. To explore this hypothesis, we analyzed a 
cohort of patients with cirrhosis with clinical char-
acteristics similar to those of the PRO-LIVER study 
Fig. 2. Correlation of factors with serum albumin. Correlation between serum albumin levels and (A) sCD40L plasma levels, (B) 
sNox2-dp serum levels, and (C) urinary excretion of isoprostane in 112 patients with liver cirrhosis. Spearman’s rank correlation 
coefficient (rs) was calculated.
Hepatology CommuniCations, april 2019BASILI, CARNEVALE, ET AL.
510
and found that serum albumin inversely correlated 
with plasma sCD40L, which partially reflects in vivo 
platelet activation,(13) as well as with markers of oxida-
tive stress, such as sNox2-dp and urinary isoprostanes. 
The inverse association between serum albumin and 
oxidative stress is important for several reasons. First, 
albumin is known to exert an antioxidant effect by 
quenching reactive oxidant species (ROS) or binding 
and inactivating free metal, such as copper and iron, 
which otherwise would catalyze ROS formation.(12,14) 
In the present study, we provide further insight into 
the albumin antioxidant property by showing an 
inverse association with the activation of Nox2, which 
is among the most important cellular producers of 
ROS and is implicated in platelet activation.(15,16) To 
further substantiate the inverse association between 
serum albumin and Nox2 activation, we performed an 
in vitro study exposing platelets to scalar concentra-
tions of albumin and demonstrated that albumin dose 
dependently inhibits agonist-induced platelet activa-
tion, coincidentally with down-regulation of Nox2 
activation and formation of isoprostanes, which are 
powerful platelet agonists(10) and are produced on acti-
vation of Nox2.(10) Inhibition of Nox2 activation is an 
important step in the mechanism of platelet activation 
because genetic deficiency of this enzyme is associated 
with impaired platelet activation(16,17) and platelet-de-
pendent thrombus formation.(10) Such in vitro data 
were corroborated by a proof-of-concept study per-
formed in 5 patients with cirrhosis who needed to be 
treated with albumin infusion. Thus, we found that, 
compared to baseline values, agonist-induced platelet 
aggregation progressively decreased for the 3 days of 
albumin infusion but later tended to return to baseline 
values at 4 days after albumin discontinuation. At the 
same time points, inhibition of platelet aggregation 
was associated with an antioxidant effect, as shown 
by decreasing sNox2 and isoprostane. Together, these 
Fig. 3. Serum levels after albumin infusion. Serum levels of (A) albumin, (B) platelet aggregation, (C) sNox2-dp, and (D) urinary 
excretion of 8-iso-PGF2α-III before time 0 (T0), 2 hours (T2h) later, 3 days (T3d) after albumin infusion, and 4 days after albumin 
discontinuation (T7d) in patients with liver cirrhosis (n = 4; *P < 0.05). *Bonferroni type adjustment was used for comparisons. Data 
represent mean ± SEM.
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findings suggest that albumin exerts an antiplatelet 
effect by inhibiting Nox2-derived ROS and eventually 
isoprostane formation.
The present study has implications and limita-
tions. Due to the cross-sectional nature of the study, 
a cause–effect relationship between serum albu-
min and thrombosis cannot be firmly substantiated. 
However, the significant association between albu-
min and PVT provides a rationale to assess if albu-
min supplementation may be a therapeutic tool for 
PVT treatment. Finally, we have partial information 
to evaluate if changes of albumin over time predict 
PVT.
In conclusion, we provide the first evidence that 
serum albumin is inversely associated with PVT and 
a rationale for randomized interventional studies to 
investigate the beneficial effects of albumin to prevent 
PVT in cirrhosis.
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P < 0.05). *Bonferroni type adjustment was used for comparisons. Data represent mean ± SEM. Abbreviations: FITC, f luorescein 
isothiocyanate; PAC1, pituitary adenylate cyclase-activating polypeptide type I receptor.
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